Alimera Sciences (ALIM) Misses Q4 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Alimera Sciences Reports Record Fourth Quarter and Full Year 2016 Financial Results
March 1, 2017 4:00 PM ESTFourth Quarter and Full Year Ended 2016 Highlights
Annual revenue increased 53% for 2016 compared to 2015Record fourth quarter 2016 revenue of $10.7 million represents an 84% increase over fourth quarter 2015Alimera expects its distributors in Italy and the Middle East to further the availability of ILUVIEN in 2017Alimera to host conference call on March 2, 2017 at 10:00 AM ETATLANTA, March 01, 2017 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a global pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic... More
